COST-EFFECTIVENESS OF IDELALISIB IN COMBINATION WITH RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN PORTUGAL

被引：0
|
作者：
Silva, M. G. [1 ]
Gouveia, M. [2 ]
Alarcao, J. [3 ]
Fiorentino, F. [3 ]
Carda, J. [4 ]
Costa, R. M. [5 ]
Mariz, J. M. [1 ]
Raposo, J. [6 ]
Borges, M. [3 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal
[2] Catolic Lisbon Sch Business & Econ, Lisbon, Portugal
[3] Univ Lisbon, Ctr Evidence Based Med, Fac Med, P-1699 Lisbon, Portugal
[4] Ctr Hosp Univ Coimbra, Coimbra, Portugal
[5] Hosp Garcia de Orta, Lisbon, Portugal
[6] Ctr Hosp Lisboa Norte, Lisbon, Portugal
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1439
引用
收藏
页码：577 / 577
页数：1
相关论文
共 50 条
  • [21] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Oluwatobi Odetola
    Shuo Ma
    Current Hematologic Malignancy Reports, 2023, 18 : 130 - 143
  • [22] COST-EFFECTIVENESS OF IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY (RR) CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) IN ENGLAND
    Hassan, F.
    Peng, S.
    Dorman, E.
    Sorensen, S.
    Thompson, G.
    Lee, J.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A441
  • [23] Combination Therapy with Lenalidomide and Rituximab in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL)
    Ferrajoli, Alessandra
    Badoux, Xavier C.
    O'Brien, Susan
    Wierda, William G.
    Faderl, Stefan
    Estrov, Zeev
    Pasia, Manolo
    Lee, Bang-Ning
    Reuben, James M.
    Kantarjian, Hagop
    Keating, Michael
    BLOOD, 2009, 114 (22) : 89 - 90
  • [24] Rituximab and Campath-1H combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL).
    Nabhan, C
    Patton, D
    Gordon, LI
    Riley, MB
    Kuzel, T
    Tallman, MS
    Rosen, ST
    BLOOD, 2003, 102 (11) : 361B - 361B
  • [25] COST-EFFECTIVENESS OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED/ REFRACTORY CHRONICLYMPHOCYTIC LEUKEMIA IN FOUR GULF COUNTRIES
    Hamad, A.
    Abdaljalil, A.
    Abdellatif, H. Y.
    Aladarbeh, Q. T.
    Al Farsi, K.
    Alhuraiji, A.
    Gamaleldin, A. M.
    Hamadah, A.
    Ismail, H. A.
    Osman, H. Y.
    Siddiqui, M.
    Taha, R. Y.
    Tannira, M.
    Pandita, R.
    VALUE IN HEALTH, 2023, 26 (06) : S67 - S68
  • [26] PENTOSTATIN, CYCLOPHOSPHAMIDE AND RITUXIMAB (PCR) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Mannina, D.
    Chiarenza, A.
    Di Raimondo, F.
    Musso, M.
    Bonanno, V.
    Nocilli, L.
    Sciarrone, A.
    Brugiatelli, M.
    HAEMATOLOGICA, 2014, 99 : 589 - 589
  • [27] COST-EFFECTIVENESS ANALYSIS OF RITUXIMAB USE IN TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA IN UKRAINE
    Mandrik, O.
    Zalis'ka, O.
    Severens, J. L.
    VALUE IN HEALTH, 2012, 15 (04) : A221 - A221
  • [28] ANALYSIS OF TREATMENT OPTIONS FOR RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Sallum, R.
    Dorman, E.
    Xu, Y.
    Tran-Kerr, K.
    O'Donnell, M.
    Sorensen, S.
    Szatkowski, A.
    Sengupta, N.
    Gaudig, M.
    VALUE IN HEALTH, 2014, 17 (07) : A616 - A616
  • [29] Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia
    Smolej, Lukas
    Doubek, Michael
    Panovska, Anna
    Simkovic, Martin
    Brychtova, Yvona
    Belada, David
    Motyckova, Monika
    Mayer, Jiri
    LEUKEMIA RESEARCH, 2012, 36 (10) : 1278 - 1282
  • [30] COST-EFFECTIVENESS OF OFATUMUMAB FOR MAINTENANCE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA
    Davies, A.
    Zou, D.
    Hurry, M.
    Bal, V.
    HAEMATOLOGICA, 2016, 101 : 146 - 146
12345